Increasingly, next generation proteins are being used over traditional monoclonal antibodies. Here we explore the challenges in developing next generation protein therapeutics and the opportunities they offer. This is an extract from a whitepaper on the different approaches, competitive advantages and challenges of next gen therapeutics over traditional mAbs.

  • Key challenges in developing next gen protein therapeutics
  • Novel opportunities for next gen protein therapeutics
  • Exploiting the opportunity to create differentiated and added-value therapeutic molecules


Download the Whitepaper

CONTINUE

Terms and Conditions  |  Privacy Policy

† You may still receive emails from us regarding any current registrations or orders.

December 9-13, 2018
Manchester Grand Hyatt San Diego
San Diego, CA

Well Characterized Biologics & Biological Assays

December 9-13, 2018
Manchester Grand Hyatt San Diego

San Diego, CA

Whitepaper: 

USE OF NEXT GENERATION PROTEIN THERAPEUTICS OVER TRADITIONAL MONOCLONAL ANTIBODIES AND DIFFERENT APPROACHES

Fix the following errors:
Hide